Journal article
Incorporating novel therapies into the treatment of older patients with classic hodgkin lymphoma
Expert review of hematology, Vol.18(9), pp.735-751
09/02/2025
DOI: 10.1080/17474086.2025.2526685
PMID: 40571966
Abstract
Outcomes of older patients with classic Hodgkin lymphoma (cHL) are inferior to those of younger patients secondary to their distinct clinical presentation, unique disease biology, increased burden of medical comorbidity, and poorer tolerance to conventional therapies. Greater attention to the objective parameters underlying patient fitness has led to the recognition of comprehensive geriatric assessments (CGA) as an important method to optimize selection for appropriate therapy intensity. Given the magnified risk associated with traditional chemotherapy in older patients with cHL, the incorporation of the novel agents brentuximab vedotin (BV) and immune checkpoint inhibitors (ICIs) into modern treatment paradigms offers promise for improved outcomes in this population.
We describe historical outcomes in older patients with cHL, the underpinnings of traditional treatment strategies, the evolving therapeutic landscape via integration of novel therapies into the frontline and relapsed/refractory settings, and the importance of contextualizing therapy selection via formal CGAs.
Novel therapies have broadened the array of therapeutic options for older patients with cHL eligible for either curative or palliative intent therapy. Further investigation into rational combinations of these drugs, together with ongoing efforts to validate cHL-specific CGAs, aim to improve outcomes for older patients across the spectrum of fitness.
Details
- Title: Subtitle
- Incorporating novel therapies into the treatment of older patients with classic hodgkin lymphoma
- Creators
- Aditya Ravindra - University of IowaEric Mou - University of Iowa
- Resource Type
- Journal article
- Publication Details
- Expert review of hematology, Vol.18(9), pp.735-751
- DOI
- 10.1080/17474086.2025.2526685
- PMID
- 40571966
- NLM abbreviation
- Expert Rev Hematol
- ISSN
- 1747-4094
- eISSN
- 1747-4094
- Publisher
- Taylor & Francis; ABINGDON
- Language
- English
- Electronic publication date
- 06/26/2025
- Date published
- 09/02/2025
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984833634102771
Metrics
2 Record Views